vimarsana.com

Page 2 - கொலம்பஸ் துணிகர கூட்டாளர்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Viralgen expands AAV vector manufacturing in Spain

Viralgen expands AAV vector manufacturing in Spain
biopharma-reporter.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biopharma-reporter.com Daily Mail and Mail on Sunday newspapers.

Investegate |Viralgen Vector Core Announcements | Viralgen Vector Core: Viralgen increases its manufacturing capacity

Investegate |Viralgen Vector Core Announcements | Viralgen Vector Core: Viralgen increases its manufacturing capacity
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

NOXXON Pharma N : announces convocation of its hybrid 2021 annual general meeting of shareholders

NOXXON ANNOUNCES CONVOCATION OF ITS HYBRID 2021 ANNUAL GENERAL MEETING OF SHAREHOLDERS Strengthening of the Supervisory Board through the binding nominations of . | May 25, 2021

NOXXON Announces Convocation of Its Hybrid 2021 Annual General Meeting of Shareholders

NOXXON Announces Convocation of Its Hybrid 2021 Annual General Meeting of Shareholders
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Private equity firm buys PTS to seize on COVID-19-fueled transformation of nanoparticle delivery

News of the takeover comes months after Arcline raised a $2.75 billion fund. (Getty/Kritchanut) A private equity group has bought Polypeptide Therapeutic Solutions for its nanoparticle drug delivery technologies. Arcline Investment Management struck the deal in the belief the success of mRNA COVID-19 vaccines has permanently accelerated the rise of nanoparticle delivery. PTS spun out from a Spanish biomedical research center in 2012 and, with the support of investors including Columbus Venture Partners, has established vehicles to transport active substances. The vehicles have multiple applications, including as non-viral vectors to deliver nucleic acids. Increased interest in that use case was a factor in the deal.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.